Safety profile of Cinacalcet Compared to conventional therapy used in treatment of CKD-sHPT at teaching hospital, Saudi Arabia

摘要: Almost all patients who have kidney failure develop sHPT. Cinacalcet is a calcimimetic agent accepted for treatment of Secondary parathyroidism in End Stage Renal Disease patients. The frequently reported adverse events with cinacalcet were hypocalcaemia, diahorrea, vomiting and nausea. A retrospective cohort study to assess the safety profile of cinacalcet compared to the conventional therapy after 6 months of use in Al-Mana Hospitals Dammam, Saudi Arabia. In the study data were taken during the period from Dec-2017 to Jul-2019. Total 81 subjects were enrolled in this study. While 40 patients were taking cinacalcet and 41 patients were taking conventional therapy. The mean age for cinacalcet group was (63.75±14.76) yrs. 25 (63%) males and 15 (37%) females). For the conventional therapy arm the mean age was (62.1±9.91) yrs. 85 (91%) males and 6 (15%) females. After 6 months treatment, 75%(30 patients) has developed Hypocalcemia (Serum calcium< 8.4 mg/dL) in patients using cinacalcet in comparison to 40%(16 patients) in the conventional therapy arm with significance (p= 0.001).Nausea was experienced by 33 patients (83%) in the patients who was taking cinacalcet compared to 8 patients (21%) who were on conventional therapy with clear significance (P= 0.00). there is significant difference in incidence of vomiting (15 patients (38%) in the cincalcet Vs. 15%(6 patients) for the conventional therapy arm (p= 0. 02) Diarrhea was reported in 4 patients on cinacalcet (10%) and 2 patients in the conventional therapy arm (5%) with= 0.414). Compared to conventional therapy, there was a significant difference in the …